Retatrutide
GLP-1 / metabolic · By Preptide Pro editorial team · Last updated
Retatrutide is a glp-1 / metabolic peptide, and it is not FDA-approved. An investigational triple agonist of the GIP, GLP-1 and glucagon receptors. In late-stage clinical trials for obesity and related conditions.
Not FDA-approvedChemistry (PubChem)
No matching PubChem compound record was found under this name.
Is Retatrutide FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Retatrutide?
PubMed lists 211 records for “retatrutide”, of which 10 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. | Rapid Commun Mass Spectrom | 2026 Dec 15 |
| GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases. | Eur J Pharmacol | 2026 Dec 10 |
| The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications. | J Diabetes Metab Disord | 2026 Dec |
| Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. | Diabetes Obes Metab | 2026 Nov |
| The First Triple Agonist for Antiobesity: Retatrutide. | Cardiol Rev | 2026 Nov-Dec 01 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.